Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLETEO: TY-9591 versus osimertinib as first-line treatment for EGFR-mutant advanced NSCLC
CTR20221053Phase 3Active
- Sponsor
- TYK Medicines
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Started Jun 2022; status: active.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221053.